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Real-Time Dynamic Carbon Dioxide Administration
A Novel Treatment Strategy for Stabilization of Periodic
Breathing With Potential Application to Central Sleep Apnea
Alberto Giannoni, MD,*‡§ Resham Baruah, MBBS,* Keith Willson, MSC,* Yoseph Mebrate, MSC,*†
Jamil Mayet, MD,* Michele Emdin, MD,‡ Alun D. Hughes, MBBS, PHD,*
Charlotte H. Manisty, MBBS,* Darrel P. Francis, MD*
London, United Kingdom; and Pisa, Italy
Objectives This study targeted carbon dioxide (CO2) oscillations seen in oscillatory ventilation with dynamic pre-emptive CO2
administration.
Background Oscillations in end-tidal CO2 (et-CO2) drive the ventilatory oscillations of periodic breathing (PB) and central sleep
apnea in heart failure (HF).
Methods Seven healthy volunteers simulated PB, while undergoing dynamic CO2 administration delivered by an auto-
mated algorithm at different concentrations and phases within the PB cycle. The algorithm was then tested in 7
patients with HF and PB.
Results In voluntary PB, the greatest reduction (74%, p  0.0001) in et-CO2 oscillations was achieved when dynamic
CO2 was delivered at hyperventilation; when delivered at the opposite phase, the amplitude of et-CO2 oscillations
increased (35%, p  0.001). In HF patients, oscillations in et-CO2 were reduced by 43% and ventilatory oscilla-
tions by 68% (both p  0.05). During dynamic CO2 administration, mean et-CO2 and ventilation levels remained
unchanged. Static CO2 (2%, constant flow) administration also attenuated spontaneous PB in HF patients (p 
0.02) but increased mean et-CO2 (p  0.03) and ventilation (by 45%, p  0.03).
Conclusions Dynamic CO2 administration, delivered at an appropriate time during PB, can almost eliminate oscillations in
et-CO2 and ventilation. This dynamic approach might be developed to treat central sleep apnea, as well as mini-
mizing undesirable increases in et-CO2 and ventilation. (J Am Coll Cardiol 2010;56:1832–7) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.053d
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Heriodic breathing (PB), Cheyne-Stokes respiration, and
entral sleep apnea (CSA) are frequently seen (1) oscillatory
atterns in heart failure (HF), associated with a worse
rognosis (1–3). Although, these ventilatory oscillations are
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ccepted May 4, 2010.riven by oscillations in CO2 (4–6), the latter are not
pecifically targeted by current treatments.
Mathematical modeling (7) suggests that carefully tar-
eting therapy within the PB cycle may fill in the troughs
f end-tidal CO2 (et-CO2) that produce hypopneas, as well
s minimizing any undesirable increase in et-CO2 that
ould cause hyperventilation and adrenergic overactivation
8–11).
See page 1838
We investigated this in 2 ways. First, dynamic CO2 was
dministered in voluntary periodic breathing (VPB) (12,13) at
ifferent timings and concentrations. Second, dynamic CO2
as administered to HF patients with spontaneous PB.
ethods
ubjects. Seven healthy subjects free of medications and 7
F patients with daytime spontaneous PB were enrolledTable 1). All HF patients were on stable contemporary
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isorders, and drugs affecting ventilatory drive. Spontaneous
B was defined as an oscillatory pattern in ventilation with
period of 60 s characterized by phases of hyperventila-
ion and central apnea (cessation of ventilatory effort for
10 s) or hypopnea (50% reduction in tidal volume, with
4% oxygen saturation) shown during a 30-min outpatient
ecording (1,14–16). All subjects gave informed consent for
he study that was approved by the NHS Research Ethics
ommittee (05/Q0404/018).
easurements. Subjects underwent baseline recordings
ecumbent, breathing through a pneumotachograph (Hans
udolph Inc., Shawnee, Kansas) attached to a Multicap
Datex Instrumentarium, Helsinki, Finland) measuring gas
oncentrations. They were monitored via electrocardiogram
Hewlett-Packard, Palo Alto, California), beat-by-beat
lood pressure and cardiac output (Finometer, Finapres
edical Systems, Amsterdam, Netherlands).
ata acquisition. Data were sampled at 1,000 Hz simul-
aneously from all devices using an analog-to-digital card
DAQCard 6062E, National Instruments, Austin, Texas)
ith LabView (version 7.0, National Instruments) and
nalyzed offline (17–19).
O2 administration system. Using a motorized valve
Fig. 1), the system delivers CO2 in any configuration of
iming and dose. Custom software (Matlab, Natick, Mas-
achusetts) (17–19) analyzes ventilation and computes the
aseline Characteristics ofealthy Subjects and HF PatientsTable 1 B seli e Charact ristics ofHealthy Subjects and HF Patients
Healthy Subjects HF Patients
n 7 7
Men 5 6
Age, yrs 34 13 77 4
BMI, kg/m2 24.3 0.7 24.1 0.5
Ejection fraction, % 59.0 5.1 18.5 7.4
Heart rate, beats/min 66.1 7.6 74.2 21.3
Cardiac output, l/min 6.5 2.4 4.1 1.2
End-tidal CO2, kPa 6.0 0.7 4.7 0.4
Oxygen saturation, % 98.4 1.1 93.2 1.3
Ventilation, l/min 7.6 1.5 8.3 1.9
NYHA functional class III/IV 3/1
Etiology
Ischemic 3
Dilative 2
Valvular 1
Alcoholic 1
Treatment
Biventricular pacemaker 4
ACE inhibitor/ARBs 7
Beta-blockers 7
Aldosterone antagonists 3
Diuretics 6
ata are expressed as mean  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
ndex; HF  heart failure; NYHA  New York Heart Association.agnitude and the phase of ventilatory oscillations ineal-time, with the ventilatory
ycle represented as a clock (peak
entilation at 0°, nadir ventila-
ion at 180°).
Dynamically titrated concen-
rations of CO2 are delivered ac-
ording to both magnitude and
hase of the current cycle. CO2
oncentration is varied smoothly,
rom 0, before peak administra-
ion, rising to a brief peak level,
nd then declining to 0 again, in a sinusoidal shape.
PB in healthy volunteers. Voluntary PB was achieved
sing computer program guidance (20). We defined the
elative amplitude of oscillation () as the ratio between
mplitude and mean, for ventilation (VEN) and et-CO2
ET-CO2). The ratio between the alpha values (e.g., ET-
O2/VEN) controls for variation in depth of ventilatory
scillations.
O2 administration protocol. The average delay between
tarting the motor and gas reaching the alveolar space was
7s corresponding to an angle of 40 (7/60  40/360). We
elivered CO2 at –40
 so that CO2 would arrive in the
lveolar space coincident with peak ventilation.
In VPB, to explore the effect of the phase of CO2
dministration, we performed replicate experiments where
O2 was delivered at –130
, –85, 5, 50, and 140. The
ffect of dose was established by delivering CO2 at –40

ith peak concentration of 1%, 2%, and 4%). In HF
atients with spontaneous PB, dynamic CO2 administration
2% at –40°) and static (2%) CO2 administration were each
ompared to baseline.
tatistical analysis. Values are presented as mean  SD
or continuous data and percentages for categorical data.
ifferences between repeated measurements were analyzed
y paired t test where p  0.05 was considered significant,
Abbreviations
and Acronyms
CSA  central sleep apnea
et-CO2  end-tidal carbon
dioxide
HF  heart failure
PB  periodic breathing
VPB  voluntary periodic
breathing
Figure 1 Overview of the System
Representation of the system used to dynamically deliver CO2 to the subject.
The reservoir of CO2 is maintained at atmospheric pressure, with delivery
dependent on the subject’s inspiration.
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Dynamic CO2 in Periodic Breathing November 23, 2010:1832–7r by analysis of variance with Bonferroni post hoc correc-
ion in cases of multiple comparisons with VPB where 6
ifferent times of administration were tested and p  0.003
as considered significant, and likewise for 3 different doses
1%, 2%, and 4%), p  0.008.
esults
ubject characteristics. Seven healthy subjects were en-
olled (Table 1), each of them able to consistently perform
PB (Table 2). Seven HF patients with spontaneous PB
Table 1) were recruited, of whom 4 had apneas and 3 only
ypopneas.
mpact of timing and peak dose of dynamic CO2 admin-
stration in VPB. The greatest reduction in size of et-CO2
scillations occurred when CO2 was delivered at –40°
Fig. 2), which is a 74% reduction below baseline (0.05 
.02 kPa vs. 0.20  0.03 kPa, p  0.0001).
ffect of VPB in Healthy Volunteers on Ventilatory and HemodynamTable 2 Effect of VPB in Healthy Volunteers on Ventilatory and
Voluntary Peri
Mean  SD
Absolute Am
of Oscilla
Ventilation, l/min 9.6 2.4 4.2 1
End-tidal CO2, kPa 5.08 0.73 0.45 0
End-tidal O2, kPa 16.14 1.36 0.94 0
Heart rate, beats/min 72.26 7.41 1.83 1
Mean arterial pressure, mm Hg 88.91 22.93 3.44 1
Cardiac output, l/min 5.59 1.72 0.32 0
PB  voluntary periodic breathing.
Figure 2 Phase of CO2 Administration in VPB
Effect of changing the phase of dynamic CO2 on end-tidal CO2 in 1 volunteer (top)
VPB  voluntary periodic breathing.The other phases of CO2 delivery were less effective in
ttenuating et-CO2 oscillations. Efficiency declined pro-
ressively as the treatment angle was moved from – 40°.
n the extreme (180° away from – 40°, approximately
rough ventilation), oscillations were 35% larger than at
aseline (0.27  0.05 kPa vs. 0.20  0.03 kPa, p 
.001) (Fig. 2).
Dynamic CO2 with peak concentration of 2% was more
ffective than 1% in attenuating et-CO2 oscillations (0.05
.02 vs. 0.13  0.03, p  0.001). However, a peak
oncentration higher than 2% did not further reduce et-
O2 oscillations (0.05  0.01 vs. 0.05  0.02, p  0.47)
Fig. 3).
ynamic CO2 administration in HF patients with spon-
aneous PB. When CO2 was delivered coincident with
eak ventilation, et-CO2 oscillations were reduced by 43%
SD mean: 0.07 0.03 untreated vs. 0.04 0.02 treated
rametersodynamic Parameters
reathing
Relative Amplitude of Oscillation
Compared With That in Ventilation
e Relative Amplitude
of Oscillation
0.42 0.15 1 (reference)
0.09 0.04 0.20 0.03
0.06 0.03 0.13 0.05
0.03 0.02 0.08 0.07
0.04 0.01 0.10 0.05
0.06 0.03 0.16 0.09
n the CO2/VEN ratio in all volunteers (bottom).ic PaHem
odic B
plitud
tion
.8
.21
.45
.30
.79
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November 23, 2010:1832–7 Dynamic CO2 in Periodic BreathingO2, p 0.01) (Figs. 4 and 5). This significant attenuation
f et-CO2 oscillations resulted in attenuation of ventilatory
scillations by 68% (SD  mean: from 0.43  0.19
ntreated to 0.14  0.09 treated, p  0.01) and not at the
ost of significantly increased et-CO2 (4.7  0.4 kPa vs.
.0  0.3 kPa, p  0.06). Nor was mean ventilation
Figure 3 Peak Dose of CO2 Administration in VPB
Effect of changing the peak dose of dynamic CO2 on end-tidal CO2 in 1 volunteer (
VPB  voluntary periodic breathing.
Figure 4 Dynamic CO2 Administration in an Example Patient W
Example of 1 patient with heart failure and daytime Cheyne-Stokes respiration effi
angle width of delivery ranging from –90° to 140° was able to abolish not only th
ing their average values. HF  heart failure; PB  periodic breathing.ignificantly increased (8.26  1.85 l/min vs. 9.41  2.71
/min, p  0.12). Mean oxygen saturation (SpO2) was
igher following dynamic CO2 administration (95.0 
.4% treated vs. 93.2  1.3% untreated, p  0.02).
oreover, the magnitude of desaturation was reduced
minimum SpO2: 93.6  1.7 vs. 89.4  1.7, p  0.01).
nd on the CO2/VEN ratio in all volunteers (bottom).
F and Spontaneous PB
sly treated with dynamic CO2. The delivery of 2% CO2 (peak dose) at 0° with an
illations in end-tidal CO2, but also the fluctuations in ventilation, without increas-top) aith H
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Dynamic CO2 in Periodic Breathing November 23, 2010:1832–7tatic CO2 administration in HF patients with sponta-
eous PB. Static CO2 also stabilized breathing (SD 
ean: of ventilation, 0.14  0.06, and of CO2, 0.03 
.01). However, static CO2 significantly increased et-CO2
5.2  0.3 kPa vs. 4.7  0.0 kPa, p  0.03) and ventilation
12.00  4.08 l/min vs. 8.26  1.85 l/min, p  0.03).
emodynamic consequences of dynamic CO2 in HF
atients with spontaneous PB. There was no hemody-
amic evidence of increased sympathetic hyperstimulation
n the HF patients with no change in heart rate (75.3 
3.5 beats/min treated vs. 74.2  21.3 beats/min untreated,
 0.32) or mean arterial pressure (61.3  8.9 mm Hg vs.
8.9  10.0 mm Hg, p  0.11).
In no patient did dynamic CO2 increase ectopy, a marker
f sympathetic activity (21). There were fewer ectopics in
atients #3 and #4 (from 37 to 14, and from 18 to 0 per
0-min recording, respectively).
iscussion
his study demonstrates the possibility of attenuating CO2
scillations that drive PB using dynamically timed CO2 ad-
inistration. However, timing is critical, the most efficacious
dministration being coincident with peak ventilation.
Because CO2 is only delivered for a small part of the PB
ycle, the total quantity of CO2 delivered is markedly
educed, thus minimizing unwanted consequences of in-
reased et-CO2, such as increased mean ventilation and
ympathetic overactivation (8–11).
eriodic breathing and CO2. Frequently in HF, with
ither preserved or reduced systolic function (1,22), the
hemoreflex is enhanced and delayed (6,23). In CSA, there
ay be sleep disruption, fatigue, adrenergic overactivation
24), and increased mortality (2). Delivery of static CO2 is
fficacious in abolishing CSA (8,9), by increasing eupneic
Figure 5 Effect of Dynamic CO2 on Spontaneous PB of HF
Dynamic CO2 administration was able to attenuate oscillations in end-tidal CO2
and ventilation in 7 heart failure patients with daytime periodic breathing.
Abbreviations as in Figure 4.O2 when wakefulness drive is lost (25), but createsndesirable elevations in mean ventilation and sympathetic
ctivity (8–11). With dynamic CO2, the average dose of
O2 delivered is lower (0.5%), compared with static CO2
2%), but achieves a 67% and 43% reduction in et-CO2
scillations in VPB and spontaneous PB, respectively.
here is a nonsignificant trend toward higher et-CO2 in the
reatment group, but the numerical size is much smaller
han that seen with static administration. Moreover, this
ay be of less significance given the positive effects on
xygen saturation. CO2 administration may not only in-
rease the eupneic CO2, but may beneficially lower pulmo-
ary capillary wedge pressure via vasodilation (26).
The minimization of dose was achieved using the follow-
ng strategy:
. CO2 was only delivered for a portion of the PB cycle.
. Delivery was gradually built up within each cycle.
. Peak delivery was dependent on magnitude of ventilatory
oscillations.
ecause breathing may only be periodic for a portion of
leep time, this algorithm would deliver CO2 only during
scillations. The algorithm was successful in both groups
espite spontaneous PB being more variable from cycle to
ycle than VPB, which has experimentally enforced regu-
arity (27).
linical implications. This might be developed for CSA if
acemasks (which are often rejected in clinical practice) (28)
ere replaced with nasal cannulas and the pneumotacho-
raph by an alternative ventilation sensor.
tudy limitations. Larger studies that go beyond this
roof-of-concept to evaluate sleep architecture are needed
o examine the effect of this administration on CSA in HF
atients and to assess whether CSA is converted to obstruc-
ive sleep apnea (29).
onclusions
his study demonstrates that dynamic CO2 administration,
hen given at the right time, almost abolishes the oscillations
n et-CO2 that drive PB. This administration is found to be
ost effective when CO2 arrives in the alveoli coincident with
yperventilation. Our results with dynamic CO2 intervention
upport the concept of apneas and hypopneas arising from
athological hypocapnia and may offer an opportunity to
evelop therapies for PB and CSA that might avoid some of
he pitfalls of static CO2 administration.
eprint requests and correspondence: Dr. Alberto Giannoni or
r. Resham Baruah, International Centre for Circulatory Health,
mperial College, 59-61 North Wharf Road, London W2 1LA,
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